OCGN ▲ +2.0% - Ocugen, Inc.
$OCGN - Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
25-SEP-2026 07:02 AM ET
Share this post
More filings for $OCGN
OCGN ▲ +4.0% - Ocugen, Inc.Nov 4, 2026OCGN ▲ +4.5% - Ocugen, Inc.Oct 14, 2026OCGN ▲ +4.5% - Ocugen, Inc.Oct 14, 2026OCGN ▼ -0.9% - Ocugen, Inc.Sep 30, 2026OCGN ▲ +1.0% - Ocugen, Inc.Sep 29, 2026OCGN ▲ +0.8% - Ocugen, Inc.Sep 1, 2026
View full $OCGN filing history →💬 Comments
Loading comments…
Leave a comment